Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial.
dosimetry
glioblastoma
non-coplanar IMRT
tumor treating fields
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
25
09
2020
revised:
06
11
2020
accepted:
04
12
2020
pubmed:
4
1
2021
medline:
22
6
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
The aim of the present study based on the PriCoTTF-phase I/II trial is the quantification of skin-normal tissue complication probabilities of patients with newly diagnosed glioblastoma multiforme treated with Tumor Treating Field (TTField) electrodes, concurrent radiotherapy, and temozolomide. Furthermore, the skin-sparing effect by the clinically applied strategy of repetitive transducer array fixation around their center position shall be examined. Low-dose cone-beam computed tomography (CBCT) scans of all fractions of the first seven patients of the PriCoTTF-phase I/II trial, used for image guidance, were applied for the dosimetric analysis, for precise TTField transducer array positioning and contour delineation. Within this trial, array positioning was varied from fixation-to-fixation period with a standard deviation of 1.1 cm in the direction of the largest variation of positioning and 0.7 cm in the perpendicular direction. Physical TTField electrode composition was examined and a respective Hounsfield Unit attributed to the TTField electrodes. Dose distributions in the planning CT with TTField electrodes in place, as derived from prefraction CBCTs, were calculated and accumulated with the algorithm Acuros XB. Dose-volume histograms were obtained for the first and second 2 mm scalp layer with and without migrating electrodes and compared with those with fixed electrodes in an average position. Skin toxicity was quantified according to Lyman's model. Minimum doses in hot-spots of 0.05 cm Normal tissue complication probabilities (NTCPs) for skin necrosis ranged from 0.005% to 1.474% (median 0.111%) for the different patients without electrodes. NTCP logarithms were significantly dependent on patient (P < 0.0001) and scenario (P < 0.0001) as classification variables. Fixed positioning of TTField arrays increased skin-NTCP by a factor of 5.50 (95%, CI: 3.66-8.27). The variation of array positioning increased skin-NTCP by a factor of only 3.54 (95%, CI: 2.36-5.32) (P < 0.0001, comparison to irradiation without electrodes; P = 0.036, comparison to irradiation with fixed electrodes). NTCP showed a significant rank correlation with D25cm Skin-NTCP calculation uncovers significant interpatient heterogeneity and may be used to stratify patients into high- and low-risk groups of skin toxicity. Array position variation may mitigate about one-third of the increase in surface dose and skin-NTCP by the TTField electrodes.
Identifiants
pubmed: 33389825
doi: 10.1002/acm2.13144
pmc: PMC7856507
doi:
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-250Subventions
Organisme : University of Duisburg-Essen
Informations de copyright
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Références
Cancer Med. 2017 Jun;6(6):1286-1300
pubmed: 28544575
Med Phys. 1997 Jan;24(1):103-10
pubmed: 9029544
Phys Med Biol. 2020 Aug 11;65(15):155016
pubmed: 32442990
Med Phys. 2006 Apr;33(4):1116-24
pubmed: 16696489
Radiat Oncol. 2018 Feb 23;13(1):31
pubmed: 29471879
Radiat Res Suppl. 1985;8:S13-9
pubmed: 3867079
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Front Oncol. 2018 Mar 13;8:51
pubmed: 29594036
Med Phys. 1992 Jul-Aug;19(4):933-44
pubmed: 1518482
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30
pubmed: 2722599
Cell Death Dis. 2017 Apr 20;8(4):e2753
pubmed: 28425987
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Radiat Oncol. 2017 Dec 29;12(1):206
pubmed: 29284495
Phys Med Biol. 2008 Jan 7;53(1):23-36
pubmed: 18182685
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35
pubmed: 2032883
Front Oncol. 2020 Apr 21;10:411
pubmed: 32373508
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1137-43
pubmed: 26883559
Eur J Cancer. 2012 Sep;48(14):2192-202
pubmed: 22608262
J Appl Clin Med Phys. 2010 Aug 26;11(4):3351
pubmed: 21081894
J Appl Clin Med Phys. 2012 May 10;13(3):3734
pubmed: 22584171
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Annu Int Conf IEEE Eng Med Biol Soc. 2018 Jul;2018:4897-4900
pubmed: 30441441
J Clin Neurosci. 2017 Aug;42:172-175
pubmed: 28427800
Radiat Oncol. 2020 Apr 19;15(1):83
pubmed: 32307022